Kidney cancer accounts for 3% of adult malignancies and is increasingly detected through advanced imaging techniques, highlighting the need for effective treatment strategies. This retrospective study assessed the safety and efficacy of a new single-probe percutaneous cryoablation system using liquid nitrogen for treating T1a renal cancers. From May 2019 to May 2022, 25 consecutive patients from two academic hospitals, with a median age of 64.8 years [IQR 59; 75.5], underwent cryoablation for 26 T1a renal tumors. These tumors had a median size of 25.3 mm [20; 30.7] and a median RENAL nephrometry score, indicating tumor complexity, of 7 [5; 9]. No major complications arose, but three non-clinically relevant perirenal hematomas were detected on post-procedure CT scans. With a median follow-up of 795 days [573; 1020], the primary local control rate at one month stood was 80.8% (21 out of 26). The five recurrent lesions, which exhibited a higher renal score (p= 0.016), were treated again using cryoablation, achieving a secondary local control rate of 100%. No patient died, and the disease-free survival rate was 92% (23 out of 25). In conclusion, single-probe percutaneous cryoablation emerges as a promising modality for managing small renal masses. Notably, recurrence rates appear influenced by RENAL nephrometry scores, suggesting a need for further research to refine the technique.
肾癌约占成人恶性肿瘤的3%，随着先进影像技术的普及，其检出率日益提高，凸显了制定有效治疗策略的必要性。本研究通过回顾性分析，评估了新型单探针经皮液氮冷冻消融系统治疗T1a期肾癌的安全性与有效性。2019年5月至2022年5月期间，两家学术医院连续纳入25例患者（中位年龄64.8岁[IQR 59; 75.5]），对26个T1a期肾肿瘤实施冷冻消融。肿瘤中位直径25.3毫米[20; 30.7]，反映肿瘤复杂程度的RENAL肾脏测量评分中位数为7分[5; 9]。术中未发生严重并发症，但术后CT检出3例无临床意义的肾周血肿。中位随访795天[573; 1020]后，一个月初始局部控制率达80.8%（26例中21例成功）。5例复发灶（其RENAL评分显著较高，p=0.016）经再次冷冻消融治疗后，二次局部控制率达到100%。随访期间无患者死亡，无病生存率为92%（25例中23例）。研究表明，单探针经皮冷冻消融是治疗小肾肿瘤的有效手段，其复发率与RENAL评分存在相关性，提示需通过进一步研究优化技术方案。
Single-Probe Percutaneous Cryoablation with Liquid Nitrogen for the Treatment of T1a Renal Tumors
肿瘤(癌症)患者之家